Plain-English translation of NCT06846346 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called combined with chemotherapy to treat advanced stomach and esophageal cancer. Researchers want to see if adding this medication to standard chemotherapy drugs (like FOLFOX, , or ) can help patients live longer and control their cancer better. The study will enroll 88 patients and is looking for people who are newly diagnosed or who have had only one previous treatment.
Current treatments for advanced stomach and esophageal cancer don't work well enough for all patients. This medication is designed to work with the body's immune system to fight cancer, and researchers believe combining it with chemotherapy might be more effective than chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive either FOLFOX chemotherapy or a different chemotherapy drug ( or ), combined with the new medication , given as infusions at a cancer center. You will have regular visits for blood tests, imaging scans, and check-ups to monitor how well the treatment is working and watch for side effects. The exact length and schedule will depend on how your cancer responds, but you should expect ongoing treatment visits over several months.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
France